Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 675

1.

DJ-1 Knockout Augments Disease Severity and Shortens Survival in a Mouse Model of ALS.

Lev N, Barhum Y, Lotan I, Steiner I, Offen D.

PLoS One. 2015 Mar 30;10(3):e0117190. doi: 10.1371/journal.pone.0117190. eCollection 2015.

PMID:
25822630
2.

GLT1 overexpression in SOD1G93A mouse cervical spinal cord does not preserve diaphragm function or extend disease.

Li K, Hala TJ, Seetharam S, Poulsen DJ, Wright MC, Lepore AC.

Neurobiol Dis. 2015 Mar 25. pii: S0969-9961(15)00082-0. doi: 10.1016/j.nbd.2015.03.010. [Epub ahead of print]

PMID:
25818008
3.

Roots to start research in amyotrophic lateral sclerosis: molecular pathways and novel therapeutics for future.

Harikrishnareddy D, Misra S, Upadhyay S, Modi M, Medhi B.

Rev Neurosci. 2015;26(2):161-81. doi: 10.1515/revneuro-2014-0057.

PMID:
25720096
4.

The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis.

Fukunaga K, Shinoda Y, Tagashira H.

J Pharmacol Sci. 2015 Jan;127(1):36-41. doi: 10.1016/j.jphs.2014.12.012. Epub 2014 Dec 24. Review.

5.

[Neuroinflammation in amyotrophic lateral sclerosis].

Endo F, Yamanaka K.

Rinsho Shinkeigaku. 2014;54(12):1128-31. doi: 10.5692/clinicalneurol.54.1128. Japanese.

PMID:
25672727
6.

Therapeutic Development in Amyotrophic Lateral Sclerosis.

Bucchia M, Ramirez A, Parente V, Simone C, Nizzardo M, Magri F, Dametti S, Corti S.

Clin Ther. 2015 Feb 6. pii: S0149-2918(15)00010-7. doi: 10.1016/j.clinthera.2014.12.020. [Epub ahead of print] Review.

PMID:
25666449
7.

Altered Functionality, Morphology, and Vesicular Glutamate Transporter Expression of Cortical Motor Neurons from a Presymptomatic Mouse Model of Amyotrophic Lateral Sclerosis.

Saba L, Viscomi MT, Caioli S, Pignataro A, Bisicchia E, Pieri M, Molinari M, Ammassari-Teule M, Zona C.

Cereb Cortex. 2015 Jan 16. pii: bhu317. [Epub ahead of print]

PMID:
25596588
8.

Glutamate protects neuromuscular junctions from deleterious effects of β-amyloid peptide and conversely: an in vitro study in a nerve-muscle coculture.

Combes M, Poindron P, Callizot N.

J Neurosci Res. 2015 Apr;93(4):633-43. doi: 10.1002/jnr.23524. Epub 2014 Dec 9.

PMID:
25491262
9.

Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.

Battaglia G, Riozzi B, Bucci D, Di Menna L, Molinaro G, Pallottino S, Nicoletti F, Bruno V.

Neurobiol Dis. 2015 Feb;74:126-36. doi: 10.1016/j.nbd.2014.11.012. Epub 2014 Nov 28.

PMID:
25434487
10.

System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.

Mesci P, Zaïdi S, Lobsiger CS, Millecamps S, Escartin C, Seilhean D, Sato H, Mallat M, Boillée S.

Brain. 2015 Jan;138(Pt 1):53-68. doi: 10.1093/brain/awu312. Epub 2014 Nov 10.

PMID:
25384799
11.

Depressed excitability and ion currents linked to slow exocytotic fusion pore in chromaffin cells of the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Calvo-Gallardo E, de Pascual R, Fernández-Morales JC, Arranz-Tagarro JA, Maroto M, Nanclares C, Gandía L, de Diego AM, Padín JF, García AG.

Am J Physiol Cell Physiol. 2015 Jan 1;308(1):C1-19. doi: 10.1152/ajpcell.00272.2014. Epub 2014 Nov 5.

PMID:
25377090
12.

Activity-dependent FUS dysregulation disrupts synaptic homeostasis.

Sephton CF, Tang AA, Kulkarni A, West J, Brooks M, Stubblefield JJ, Liu Y, Zhang MQ, Green CB, Huber KM, Huang EJ, Herz J, Yu G.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4769-78. doi: 10.1073/pnas.1406162111. Epub 2014 Oct 16.

13.

GLT-1 transporter: an effective pharmacological target for various neurological disorders.

Soni N, Reddy BV, Kumar P.

Pharmacol Biochem Behav. 2014 Dec;127:70-81. doi: 10.1016/j.pbb.2014.10.001. Epub 2014 Oct 13.

PMID:
25312503
14.

The glutamate hypothesis in ALS: pathophysiology and drug development.

Blasco H, Mavel S, Corcia P, Gordon PH.

Curr Med Chem. 2014;21(31):3551-75.

PMID:
25245510
15.

Neuroprotective agents target molecular mechanisms of disease in ALS.

Zhu Y, Fotinos A, Mao LL, Atassi N, Zhou EW, Ahmad S, Guan Y, Berry JD, Cudkowicz ME, Wang X.

Drug Discov Today. 2015 Jan;20(1):65-75. doi: 10.1016/j.drudis.2014.08.016. Epub 2014 Sep 6.

PMID:
25205348
16.

VEGF levels in CSF and serum in mild ALS patients.

Gao L, Zhou S, Cai H, Gong Z, Zang D.

J Neurol Sci. 2014 Nov 15;346(1-2):216-20. doi: 10.1016/j.jns.2014.08.031. Epub 2014 Aug 29.

PMID:
25204587
17.

Novel NMDA receptor-specific desensitization/inactivation produced by ingestion of the neurotoxins, β-N-methylamino-L-alanine (BMAA) or β-N-oxalylamino-L-alanine (BOAA/β-ODAP).

Koenig JH, Goto JJ, Ikeda K.

Comp Biochem Physiol C Toxicol Pharmacol. 2015 Jan;167:43-50. doi: 10.1016/j.cbpc.2014.08.006. Epub 2014 Sep 3.

PMID:
25193276
18.

Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: Putative mechanism for manganese-induced neurotoxicity.

Karki P, Smith K, Johnson J Jr, Aschner M, Lee E.

Neurochem Int. 2014 Aug 13. pii: S0197-0186(14)00185-5. doi: 10.1016/j.neuint.2014.08.002. [Epub ahead of print] Review.

PMID:
25128239
19.

Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model.

Ari C, Poff AM, Held HE, Landon CS, Goldhagen CR, Mavromates N, D'Agostino DP.

PLoS One. 2014 Jul 25;9(7):e103526. doi: 10.1371/journal.pone.0103526. eCollection 2014.

20.

Therapeutic targeting of epigenetic components in amyotrophic lateral sclerosis (ALS).

Lee J, Ryu H, Keum G, Yoon YJ, Kowall NW, Ryu H.

Curr Med Chem. 2014;21(31):3576-82.

PMID:
25005187
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk